Institut Curie attending the meeting of ASCO in Chicago
- Saturday, June, 1st 9am: Pr Jean-Yves Pierga - Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG) — COMET study.
- Medical oncologist Christophe Le Tourneau is head of the Early Clinical Trials department (D3i) at Institut Curie and professor of medicine at Paris-Saclay, and will be on hand to share the latest results from a completely innovative technique with the international medical community. The technique in question involves injecting the tumor with hafnium (an inert metal) nanoparticles prior to radiotherapy, thus enhancing the effects of radiation. Called NBTXR3, these particles are being developed by French biotechnology company Nanobiotix, and have already proved their worth in treating soft tissue sarcomas. This time, they were used to treat patients with ENT cancers. The results? Nine out of the 13 patients saw their tumors disappear!
This new strategy is based on promising innovative treatment for older patients or those with contraindications for heavy treatment such as chemotherapy
explains Prof. Christophe Le Tourneau.
- Dr Sylvie Bonvalot, Institut Curie surgeon Dr. Sylvie Bonvalot led an exceptional global study into treating sarcoma.
She is presenting her main findings at the ASCO Annual Meeting: some patients may benefit from radiotherapy prior to undergoing surgery on their tumors. Learn more on her presentation at ASCO.
- François Doz, pediatric oncologist at the SIREDO center (treatment, innovation, and cancerology research for children, teenagers and young adults) and professor of pediatrics at the Université Paris Descartes, is the last main speaker, with an oral presentation of the findings of an international multicenter study on cancers with NTRK gene fusions. In the study, researchers focused on a new drug, larotrectinib, which has just been approved by the American Food and Drugs Administration (FDA). But can this drug pass through the blood-brain barrier to impact on tumors in the central nervous system?
The results aren’t as spectacular as those for tumors outside the central nervous system, but they’re nevertheless encouraging, in both children and adults alike
explains François Doz
The process requires a molecular diagnosis of the tumors to be carried out, in order to identify those that carry this anomaly, and which may benefit from the treatment. Institut Curie’s molecular genetics platform (the Somatic Genetics Unit) is ready for action, and has already carried out analysis for many patients who took part in the study.
- Dr. Paul Cottu, deputy head of Institut Curie’s Medical Oncology department, will be presenting the latest findings from the Canto study. Launched in 2012, this large-scale Unicancer study aims to improve quality of life and health levels for women with early-stage breast cancer. As part of the study, over 12,000 women around France are being monitored, with over 2,000 of them at Institut Curie, making the institute the study’s biggest recruitment center. Paul Cottu, a member of the CANTO Study’s Executive Committee, will be revealing new information on side effects and neurological effects in particular.
The fascinating results revealed two key phenomena: Firstly, that these side effects were reported, even in patients who had not undergone chemotherapy, albeit with different clinical presentations. And secondly, that significant discrepancies were noted in the first year following treatment: some women reported that the side effects vanished rapidly, while others showed delayed onset. Researchers are aiming to pinpoint the factors behind such varying clinical presentations in order to better anticipate these potential difficulties and to offer women targeted, tailored care.